栓塞微球应用于肝动脉化疗栓塞治疗乏血供肝癌的临床观察  

Efficacy of embolism microspheres in hepatic arterial chemoembolization for hypovascular liver cancer

作　　者：张英[1] 邓俊[1] 周颜[1] 陆忠华[1] 姚悦萍[1] 吴晓霞[1] 陈卫[1] ZHANG Ying DENG Jun ZHOU Yah LU Zhong-hua YAO Yue-ping WU Xiao-xia CHEN Wei(Department of Interventional Oncology, The Fifth People＇s Hospital of Wuxi ,Wuxi 214007, China)

机构地区：[1]江苏省无锡市第五人民医院肿瘤介入科,无锡214007

出　　处：《中国肿瘤临床与康复》2017年第5期533-536,共4页Chinese Journal of Clinical Oncology and Rehabilitation

基　　金：中国肝炎基金会天晴肝病基金(TQGB20120030);无锡市卫生局项目(MD201204)

摘　　要：目的探讨栓塞微球应用于肝动脉化疗栓塞(TACE)治疗乏血供肝癌的临床疗效。方法选取2011年6月至2013年12月间无锡市第五人民医院收治的60例原发性肝癌患者,采用随机数表法分为研究组与对照组,每组30例。研究组患者采用栓塞微球为栓塞剂,对照组以碘化油加明胶海绵为栓塞剂,患者均至少经过两次肝动脉化疗栓塞术后,比较两组患者肿瘤病灶近期变化、不良反应及生存时间。结果术后研究组患者肝功能损害指标谷丙转氨酶(ALT)值高于对照组患者,差异有统计学意义(P<0.05)。研究组患者和对照组患者的总有效率分别为40.0%和20.0%,疾病控制率分别为93.3%和70.0%,差异有统计学意义(P<0.05)。研究组患者18个月生存率优于对照组患者,研究组患者和对照组患者中位生存时间分别为11个月和8个月,差异均有统计学意义(均P<0.05)。结论以栓塞微球为栓塞剂的肝动脉化疗栓塞对乏血供肝癌具有一定的疗效,值得临床进一步研究。Objective To evaluate the clinical efficacy of the embolism microspheres used as em- bolic agents in the hepatic arterial chemoembolization （TACE）for hypovascular liver cancer. Methods Sixty patients with primary liver cancer treated at The Fifth People＇s Hospital of Wuxi from June 2011 to De- cember 2013 were selected. Using a random number table, patients were divided into a study group and a control group, with 30 patients in each group. Patients in the study group were given embolism microspheres as embolic agents and patients in the control group were given Iodized oil and gelatin sponge as embolic a- gents. Each patient had at least two TACEs. Recent changes in tumor lesions, adverse reactions and surviv- al time were compared between the two groups. Results Hepatic dysfunction was much more serious in the study group than in the control group （ P 〈 0. 05 ）. There ws no significant difference in the overall efficacy between the two groups （40.0% in the study group vs 20.0% in the control group, P 〉 0. 05 ）. Disease control rate was 93.3% and 70. 0% respectively （ P 〈 0.05 ）. The 18-month survival was better in the stud- y group than in the control group （ P 〈 0.05 ）. The median survival time was 11 months and 8 months for the study group and the control group respectively （ P 〈 0.05 ）. Conclusion As embolie agents, TACE shows certain efficacy for hypovascular liver cancer, which deserves clinical expansion.

关 键 词：原发性肝肿瘤 乏血供 栓塞微球 

分 类 号：R735.7[医药卫生—肿瘤]